Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-24T00:38:16.914Z Has data issue: false hasContentIssue false

Chapter 37 - Neuromuscular disorders

from Section 11 - Neurology

Published online by Cambridge University Press:  05 September 2013

Michael F. Lubin
Affiliation:
Emory University, Atlanta
Thomas F. Dodson
Affiliation:
Emory University, Atlanta
Neil H. Winawer
Affiliation:
Emory University, Atlanta
Get access

Summary

Neuromuscular disease in surgical patients can be divided into disorders of the neuromuscular junction, peripheral nerves, and muscle.

Myasthenia gravis

Of all the neuromuscular diseases, myasthenia gravis probably has the most significant implications for surgical patients [1]. This disorder results from an autoimmune attack on the acetylcholine receptors of the postsynaptic (muscle) side of the neuromuscular junction. Characteristic clinical features include fluctuating weakness and fatigue, usually involving the extraocular muscles and eyelids (producing diplopia and ptosis). Weakness of the limbs can be severe, sometimes resulting in almost total paralysis. Sensation and deep tendon reflexes remain intact. Respiratory muscle weakness is common and can be fatal. The introduction of practical mechanical ventilation has resulted in a dramatic decrease in the mortality rate.

Although the clinical features of myasthenia gravis are sufficiently characteristic in some cases, confirmatory tests are usually necessary [2]. The acetylcholine receptor (AchR)- antibody level is elevated in over 80% of patients with myasthenia gravis. Elevated levels of this antibody are extremely specific for this disease [3]. As a result the AchR-antibody serum test is typically the first step in confirming the diagnosis, and the presence of elevated levels eliminates the need for additional confirmatory testing. In antibody-negative patients or when faced with an acutely symptomatic patient, the edrophonium test is often used. Electrodiagnostic studies (repetitive nerve stimulation and single fiber electromyography) are often useful, particularly in antibody-negative patients or patients with cardiac disease or asthma, in whom edrophonium is relatively contraindicated. The characteristic finding on 2- to 3-Hz repetitive motor nerve stimulation is a progressive decrease in the amplitude of the motor response. Single fiber electromyography may reveal the presence of jitter or blocking (a difference in the timing of activation or a failure of neuromuscular transmission in one of a pair of muscle fibers within a motor unit).

Type
Chapter
Information
Medical Management of the Surgical Patient
A Textbook of Perioperative Medicine
, pp. 404 - 410
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Johns, TR, Howard, JF, eds. Myasthenia gravis. Semin Neurol 1982; 2: 193–280.CrossRefGoogle Scholar
Phillips, LH, Melnick, PA.Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990; 10: 62–9.CrossRefGoogle ScholarPubMed
Somnier, FE.Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1993; 56: 496–504.CrossRefGoogle ScholarPubMed
Finley, JC, Pascuzzi, RM.Rational therapy of myasthenia gravis. Semin Neurol 1990; 10: 70–82.CrossRefGoogle ScholarPubMed
Bromberg, MB, Wald, JJ, Forshew, DA, Feldman, EL, Albers, JW.Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 1997; 150: 59–62.CrossRefGoogle ScholarPubMed
Myasthenia Gravis Clinical Study Group. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993; 56: 1157–63.CrossRefGoogle Scholar
Tindall, RS, Phillips, JT, Rollins, JA, Wells, L, Hall, K.A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993; 681: 539–51.CrossRefGoogle ScholarPubMed
Tindall, RS, Rollins, JA, Phillips, JT, Greenlee, RG, Wells, L, Belendiuk, G.Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719–24.CrossRefGoogle ScholarPubMed
Hauser, RA, Malek, AR, Rosen, R.Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51: 912–13.CrossRefGoogle ScholarPubMed
Ciafoloni, E, Massey, JM, Tucker-Lipscomb, B, Sanders, DB.Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56: 97–9.CrossRefGoogle Scholar
Gronseth, GS, Barohn, RJ.Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 2000; 55: 7–15.CrossRefGoogle Scholar
Arsura, EL, Bick, A, Brunuer, NC et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365–8.CrossRefGoogle ScholarPubMed
De Boer, HD, van Egmond, J, Driessen, JJ, Booij, LH.Sugammadex in patients with myasthenia gravis. Anaesthesia 2010; 65: 653.CrossRefGoogle ScholarPubMed
Wittbrodt, ET.Drugs and myasthenia gravis: an update. Arch Intern Med 1997; 157: 399–408.CrossRefGoogle ScholarPubMed
Howard, JF.Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10: 89–102.CrossRefGoogle ScholarPubMed
Krendel, D.Hypermagnesemia and neuromuscular transmission. Semin Neurol 1990; 10: 42–5.CrossRefGoogle ScholarPubMed
Pascuzzi, RM, Kim, YI.Lambert–Eaton syndrome. Semin Neurol 1990; 10: 35–41.CrossRefGoogle ScholarPubMed
Murray, MJ, Cowen, J, De Block, H et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30: 142–56.CrossRefGoogle ScholarPubMed
Upton, RM, McComas, AJ.The double crush in nerve entrapment syndromes. Lancet 1973; 11: 359–62.CrossRefGoogle Scholar
Stewart, JD, ed. The radial nerve. In Focal Peripheral Neuropathies. New York, NY: Elsevier Science Publishing; 1987, pp. 194–210.Google Scholar
Stewart, JD, ed. The ulnar nerve. In Focal Peripheral Neuropathies. New York, NY: Elsevier Science Publishing; 1987, pp. 163–93.Google Scholar
Stewart, JD, ed. The common peroneal nerve. In Focal Peripheral Neuropathies. New York, NY: Elsevier Science Publishing; 1987, pp. 290–306.Google Scholar
Warner, MA, Warner, DO, Harper, CM, Schroeder, DR, Maxson, PM.Lower extremity neuropathies associated with lithotomy positions. Anesthesiology 2000; 93: 938–42.CrossRefGoogle ScholarPubMed
Sharma, AD, Parmley, CL, Sreeram, G, Grocott, HP.Peripheral nerve injures during cardiac surgery: risk factors, diagnosis, prognosis and prevention. Anesth Analg 2000; 91: 1358–69.CrossRefGoogle Scholar
Stewart, JD.The femoral and saphenous nerves. In Focal Peripheral Neuropathies. New York, NY: Elsevier Science Publishing; 1987, pp. 322–32.Google Scholar
Hughes, RAC, ed. Epidemiology. In Guillain–Barré Syndrome. London: Springer-Verlag; 1990, pp. 101–19.CrossRefGoogle Scholar
Arnason, BG, Asbury, AK.Idiopathic polyneuritis after surgery. Arch Neurol 1968; 18: 500–7.CrossRefGoogle ScholarPubMed
Guillain–Barré Syndrome Study Group. Plasmapheresis and acute Guillain–Barré syndrome. Neurology 1985; 35: 1096–104.CrossRefGoogle Scholar
Van der Meché, FGA, Schmitz, PIM.A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123–9.CrossRefGoogle ScholarPubMed
Hughes, RA, Swan, AV, van Doorn, PA.Intravenous immunoglobulin for Guillain- Barré syndrome. Cochrane Database Syst Rev. 2010; 6: CD002063.Google ScholarPubMed
Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré Syndrome. Lancet 1997; 349: 225–30.CrossRefGoogle Scholar
Hermans, G, De Jonghe, B, Bruyninckx, F, Van den Berghe, G.Clinical review: critical illness polyneuropathy and myopathy. Crit Care 2008; 12: 238–46.CrossRefGoogle ScholarPubMed
Bolton, CF.Electrophysiologic studies of critically ill patients. Muscle Nerve 1987; 10: 129–35.CrossRefGoogle ScholarPubMed
Bolton, CF, Gilbert, JJ, Hahn, AF, Sibbald, WJ.Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47: 1223–31.CrossRefGoogle ScholarPubMed
Bolton, CF, Laverty, DA, Brown, JD et al. Critically ill polyneuropathy: electrophysiological studies and differentiation form Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1986; 49: 563–73.CrossRefGoogle Scholar
Witt, NJ, Zochodne, DW, Bolton, CF et al. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991; 99: 176–84.CrossRefGoogle ScholarPubMed
Rubin, DI.Neuralgic amyotrophy: clinical features and diagnostic evaluation. Neurologist 2001; 7: 350–6.CrossRefGoogle ScholarPubMed
Gromert, GA.Malignant hyperthermia. In Engel, AC, Bank, BQ, eds. Myology. New York, NY: McGraw-Hill; 1986, pp. 1763–84.Google Scholar
Baraka, AS, Jalbout, ML.Anesthesia and myopathy. Curr Opin Anaesthesiol 2002; 15: 371–6.CrossRefGoogle ScholarPubMed
Hogan, K.The anesthetic myopathies and malignant hyperthermias. Curr Opin Neurol 1998; 11: 469–76.CrossRefGoogle ScholarPubMed
MacFarlane, IA, Rosenthal, FD.Severe myopathy after status asthmaticus. Lancet 1977; 2: 615.CrossRefGoogle ScholarPubMed
Latronico, N, Fenzi, F, Recupero, D et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1570–82.CrossRefGoogle ScholarPubMed
Hund, E.Myopathy in critically ill. Crit Care Med 1999; 27: 2544–7.CrossRefGoogle ScholarPubMed
Rich, MM, Bird, SJ, Raps, EC, McCluskey, LF, Teener, JW.Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997; 20: 665–73.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Trojaborg, W, Weimer, LH, Hays, AP.Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy – a reappraisal. Clin Neurophysiol 2001; 112: 1586–93.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×